The Netherlands
VarmX is a promising biotech company from The Netherlands, established in 2016. Focusing on the critical sectors of hemostasis and thrombosis, the company has its roots as a spin-off from the Leiden University Medical Center (LUMC). Its mission to develop therapeutic proteins aims to address bleeding complications in patients using oral factor Xa inhibitors.
The company's flagship compound, VMX-C001, is making strides towards ensuring safer patient outcomes during emergency surgeries. VarmX has gained significant attention from the investment community, underlined by a successful Series B financing round of €32 million in 2020 and a subsequent Series B2 round of equal stature in May 2023. These financial infusions are propelling the company towards regulatory milestones, including the preparation for pivotal trials and IND approval.
Recently, an acquisition investment valued at $117 million on 01 September 2025 from CSL, highlights VarmX's potential in revolutionizing therapeutic approaches in hemostasis.
